Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Nov 30, 2021 8:59pm
175 Views
Post# 34183097

RE:RE:RE:RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics

RE:RE:RE:RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics Taken from yahoo.com message board :

ONCY's AWARE-1 WoW study's primary endpoint was CeLTiLs score, a metric for quantifying the changes in tumor cellularity (Cel) and tumor infiltrated lymphocytes (TILs), where an increase in CelTIL is associated with a favorable response to treatment in early breast cancer. To date a 72% CelTIL response rate has been reported. More to come on this study given the plethora of data that has been generated,

Meanwhile  the rationale for ONCY's Phase 2 IRENE clinical study is to demonstrate that the administration of pelareorep primes the tumor microenvironment (TME) for enhanced tumor response to INCYTE's PD-1 inhibitor retifanlimab. This benefit of pelareorep being able to turn cold tumors hot and overcome the immunosuppressive TME in advance of the addition of immune checkpoint inhibition by stimulating the innate and adaptive immune system, has already been demonstrated in the AWARE-1 study which was designed to measure  CelTiLs score and not the priming of the TME by pelareorep.

Consequently the design of each study is different and measures separate yet related metrics, which traders with no scientific or clinical knowledge are trying to spin into something else.

With ONCY already demonstrating that pelareorep primes the TME in advance of the immune checkpoint inhibitor atezolizumab in the AWARE-1 study, positive results in ONCY's Phase 2 study will demonstrate reproducibility of results with a different immune checkpoint inhibitor. Otherwise,  the results will demonstrate that pelareorep is synergistic with one or the other ICI or more expectedly with both ICIs.

ONCY response ...... FDA requests are being met with the intent of reducing the number of patients and cost to run a Phase 3 study - both agreeable to a big pharma/biotech partner.


<< Previous
Bullboard Posts
Next >>